Drug Trial Radar · NCT05829655
Measuring Acute Drug Demand in Humans
Last checked: Nov 20, 2026Latest source record: Jun 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
75
Planned (sponsor's estimate)
Start
Aug 8, 2023
Primary completion
Jan 1, 2028
Study completion Jan 1, 2028
Sponsor
- Lead sponsor
- University of Maryland, BaltimoreAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Institute on Drug Abuse (NIDA)
- First posted
- Apr 26, 2023
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This research is being done to evaluate whether suvorexant may reduce the use of, subjective liking, and demand for various drugs.
Conditions
- Opioid Use Disorder
- Opioid Dependence
Interventions
Drug A (Blinded Drug)Drug
Participants will receive a double-blinded oral study medication as part of their daily sessions and will provide feedback regarding the effects of the medication on various measures. Though the study medications are FDA approved, they are being used here for a non-FDA approved purpose (though the FDA has provided permission to use these drugs in this study).
Drug B (Blinded Drug)Drug
Participants will receive a double-blinded oral study medication as part of their daily sessions and will provide feedback regarding the effects of the medication on various measures. Though the study medications are FDA approved, they are being used here for a non-FDA approved purpose (though the FDA has provided permission to use these drugs in this study).
Drug C (Blinded Drug)Drug
Participants will receive a double-blinded oral study medication as part of their daily sessions and will provide feedback regarding the effects of the medication on various measures. Though the study medications are FDA approved, they are being used here for a non-FDA approved purpose (though the FDA has provided permission to use these drugs in this study).
Drug D (Blinded Drug)Drug
Participants will receive a double-blinded oral study medication as part of their daily sessions and will provide feedback regarding the effects of the medication on various measures. Though the study medications are FDA approved, they are being used here for a non-FDA approved purpose (though the FDA has provided permission to use these drugs in this study).
Suvorexant (20mg/day)Drug
Double blind administration of suvorexant once per day during residential stay until discharge.
PlaceboDrug
Double blind administration of placebo once per day during residential stay until discharge.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Demand IntensityTime frame: Upon completion of experimental session (~8 hours post drug administration)
- Demand ElasticityTime frame: Upon completion of experimental session (~8 hours post drug administration)
- Cross-Price ElasticityTime frame: After Experimental Session 4
Locations
1 site in 1 country. Site status is shown where the registry gives one.
General Clinical Research Center
Baltimore, Maryland · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.